ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 36 filers reported holding ESSA PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,924,491 | +23.7% | 4,182,683 | +8.1% | 0.00% | 0.0% |
| Q2 2023 | $10,449,216 | +13.3% | 3,870,080 | +24.6% | 0.00% | 0.0% |
| Q1 2023 | $9,222,489 | +82.4% | 3,105,215 | +54.8% | 0.00% | 0.0% |
| Q4 2022 | $5,056,322 | +31.9% | 2,006,477 | -4.7% | 0.00% | 0.0% |
| Q3 2022 | $3,833,000 | -66.8% | 2,106,019 | -42.6% | 0.00% | -50.0% |
| Q2 2022 | $11,559,000 | +20.6% | 3,669,680 | +136.7% | 0.00% | +100.0% |
| Q1 2022 | $9,581,000 | +13394.4% | 1,550,530 | +30707.3% | 0.00% | – |
| Q4 2021 | $71,000 | -92.2% | 5,033 | -95.6% | 0.00% | – |
| Q3 2021 | $912,000 | -93.6% | 113,981 | -77.1% | 0.00% | -100.0% |
| Q2 2021 | $14,194,000 | -14.7% | 496,809 | -13.3% | 0.00% | 0.0% |
| Q1 2021 | $16,644,000 | +198.9% | 572,967 | +22.8% | 0.00% | +100.0% |
| Q4 2020 | $5,568,000 | +132.7% | 466,714 | +34.6% | 0.00% | – |
| Q3 2020 | $2,393,000 | +206.8% | 346,819 | +175.5% | 0.00% | – |
| Q2 2020 | $780,000 | +1757.1% | 125,865 | +1558.5% | 0.00% | – |
| Q4 2019 | $42,000 | – | 7,589 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soleus Capital Management, L.P. | 4,145,117 | $12,310,997 | 1.28% |
| BVF INC/IL | 8,748,629 | $25,983,428 | 0.95% |
| Ally Bridge Group (NY) LLC | 236,583 | $702,652 | 0.92% |
| PFM Health Sciences, LP | 4,161,461 | $12,359,539 | 0.55% |
| Bellevue Group AG | 7,898,583 | $23,458,792 | 0.34% |
| Rhenman & Partners Asset Management AB | 356,500 | $1,051,675 | 0.12% |
| Orbimed Advisors | 1,198,337 | $3,559,061 | 0.07% |
| Privium Fund Management (UK) Ltd | 20,032 | $61,498 | 0.05% |
| Rock Springs Capital Management LP | 524,944 | $1,559,084 | 0.04% |
| Hunting Hill Global Capital, LLC | 10,000 | $29,700 | 0.02% |